Literature DB >> 27637301

Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags.

Astrid Eijkelenboom1, Eveline J Kamping2, Annemiek W Kastner-van Raaij1, Sandra J Hendriks-Cornelissen1, Kornelia Neveling2, Roland P Kuiper2, Alexander Hoischen3, Marcel R Nelen2, Marjolijn J L Ligtenberg4, Bastiaan B J Tops5.   

Abstract

Sequencing of tumor DNA to detect genetic aberrations is becoming increasingly important, not only to refine cancer diagnoses but also to predict response to targeted treatments. Next-generation sequencing is widely adopted in diagnostics for the analyses of DNA extracted from routinely processed formalin-fixed, paraffin-embedded tissue, fine-needle aspirates, or cytologic smears. PCR-based enrichment strategies are usually required to obtain sufficient read depth for reliable detection of genetic aberrations. However, although the read depth relates to sensitivity and specificity, PCR duplicates generated during target enrichment may result in overestimation of library complexity, which may result in false-negative results. Here, we report the validation of a 23-gene panel covering 41 hotspot regions using single-molecule tagging of DNA molecules by single-molecule molecular inversion probes (smMIPs), allowing assessment of library complexity. The smMIP approach outperforms Sanger and Ampliseq-Personal Genome Machine-based sequencing in our clinical diagnostic setting. Furthermore, single-molecule tags allow consensus sequence read formation, allowing detection to 1% allele frequency and reliable exclusion of variants to 3%. The number of false-positive calls is also markedly reduced (>10-fold), and our panel design allows for distinction between true mutations and deamination artifacts. Not only is this technique superior, smMIP-based library preparation is also scalable, easy to automate, and flexible. We have thus implemented this approach for sequence analysis of clinical samples in our routine diagnostic workflow.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27637301     DOI: 10.1016/j.jmoldx.2016.06.010

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  42 in total

1.  CTNNB1-mutated melanocytic lesions with DPN like features: a distinct subtype of melanocytic tumors? A report of two cases.

Authors:  B T Teunissen; G J Knuiman; A Eijkelenboom; C A P Wauters; S Wouda; W A M Blokx
Journal:  Virchows Arch       Date:  2017-10-31       Impact factor: 4.064

2.  Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life.

Authors:  Rocio Acuna-Hidalgo; Hilal Sengul; Marloes Steehouwer; Maartje van de Vorst; Sita H Vermeulen; Lambertus A L M Kiemeney; Joris A Veltman; Christian Gilissen; Alexander Hoischen
Journal:  Am J Hum Genet       Date:  2017-06-29       Impact factor: 11.025

3.  Two types of primary mucinous ovarian tumors can be distinguished based on their origin.

Authors:  Michiel Simons; Femke Simmer; Johan Bulten; Marjolijn J Ligtenberg; Harry Hollema; Shannon van Vliet; Richarda M de Voer; Eveline J Kamping; Dirk F van Essen; Bauke Ylstra; Lauren E Schwartz; Yihong Wang; Leon F Massuger; Iris D Nagtegaal; Robert J Kurman
Journal:  Mod Pathol       Date:  2019-11-06       Impact factor: 7.842

4.  Ultrasensitive Detection of Chimerism by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing of Copy Number Deletion Polymorphisms.

Authors:  David Wu; Adam Waalkes; Kelsi Penewit; Stephen J Salipante
Journal:  Clin Chem       Date:  2018-03-16       Impact factor: 8.327

5.  RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment.

Authors:  V Tack; M J L Ligtenberg; A G Siebers; P D M Rombout; P D Dabir; R D A Weren; J H J M van Krieken; E M C Dequeker
Journal:  Virchows Arch       Date:  2018-01-15       Impact factor: 4.064

6.  Unraveling Neuroendocrine Gallbladder Cancer: Comprehensive Clinicopathologic and Molecular Characterization.

Authors:  Tessa J J de Bitter; Leonie I Kroeze; Philip R de Reuver; Shannon van Vliet; Elisa Vink-Börger; Daniel von Rhein; Erik A M Jansen; Iris D Nagtegaal; Marjolijn J L Ligtenberg; Rachel S van der Post
Journal:  JCO Precis Oncol       Date:  2021-03-08

7.  Intra-Tumoral Genomic Heterogeneity in Rectal Cancer: Mutational Status Is Dependent on Preoperative Biopsy Depth and Location.

Authors:  Floris A Vuijk; Carlijn van de Water; Shannon Lent-van Vliet; Maxime J M van der Valk; Femke Simmer; Cornelis J H van de Velde; Alexander L Vahrmeijer; Iris D Nagtegaal; Denise E Hilling
Journal:  Cancers (Basel)       Date:  2021-05-09       Impact factor: 6.639

8.  Digoxin treatment reactivates in vivo radioactive iodide uptake and correlates with favorable clinical outcome in non-medullary thyroid cancer.

Authors:  Thomas Crezee; Marika H Tesselaar; James Nagarajah; Willem E Corver; Johannes Morreau; Catrin Pritchard; Shioko Kimura; Josephina G Kuiper; Ilse van Engen-van Grunsven; Jan W A Smit; Romana T Netea-Maier; Theo S Plantinga
Journal:  Cell Oncol (Dordr)       Date:  2021-02-03       Impact factor: 6.730

9.  IGF2 is a potential factor in RAI-refractory differentiated thyroid cancer.

Authors:  Thomas Crezee; Marika H Tesselaar; Martin Jaeger; Katrin Rabold; Willem E Corver; Hans Morreau; Adriana C H Van Engen-Van Grunsven; Jan W A Smit; Romana T Netea-Maier; Theo S Plantinga
Journal:  Oncol Lett       Date:  2021-06-06       Impact factor: 2.967

10.  Profiling of the metabolic transcriptome via single molecule molecular inversion probes.

Authors:  Tessa de Bitter; Carlijn van de Water; Corina van den Heuvel; Carolien Zeelen; Astrid Eijkelenboom; Bastiaan Tops; Egbert Oosterwijk; Dimitar Kolev; Peter Mulders; Mark Ter Laan; Sanne van Lith; William Leenders
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.